Literature DB >> 19846852

X-linked thrombophilia with a mutant factor IX (factor IX Padua).

Paolo Simioni1, Daniela Tormene, Giulio Tognin, Sabrina Gavasso, Cristiana Bulato, Nicholas P Iacobelli, Jonathan D Finn, Luca Spiezia, Claudia Radu, Valder R Arruda.   

Abstract

We report a case of juvenile thrombophilia associated with a substitution of leucine for arginine at position 338 (R338L) in the factor IX gene (factor IX-R338L). The level of the mutant factor IX protein in plasma was normal, but the clotting activity of factor IX from the proband was approximately eight times the normal level. In vitro, recombinant factor IX-R338L had a specific activity that was 5 to 10 times as high as that in the recombinant wild-type factor IX. The R338 substitution causes a gain-of-function mutation, resulting in factor IX that is hyperfunctional. 2009 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19846852     DOI: 10.1056/NEJMoa0904377

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  98 in total

Review 1.  Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders.

Authors:  Antonio Girolami; Elisabetta Cosi; Silvia Ferrari; Annamaria Lombardi; Fabrizio Fabris
Journal:  Clin Appl Thromb Hemost       Date:  2017-08-04       Impact factor: 2.389

2.  Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.

Authors:  Ru Zhang; Qiang Wang; Lin Zhang; Saijuan Chen
Journal:  Front Med       Date:  2015-02-07       Impact factor: 4.592

Review 3.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

Review 4.  Advances and innovations in haemophilia treatment.

Authors:  Rob Peters; Tim Harris
Journal:  Nat Rev Drug Discov       Date:  2018-06-08       Impact factor: 84.694

5.  Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

Authors:  Brian Cooley; William Funkhouser; Dougald Monroe; Ashley Ezzell; David M Mann; Feng-Chang Lin; Paul E Monahan; Darrel W Stafford
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

6.  Moving forward toward a cure for hemophilia B.

Authors:  Thierry VandenDriessche; Marinee K Chuah
Journal:  Mol Ther       Date:  2015-05       Impact factor: 11.454

7.  Gene therapy for hemophilia: the clot thickens.

Authors:  Katherine A High
Journal:  Hum Gene Ther       Date:  2014-11       Impact factor: 5.695

8.  Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

Authors:  Lindsey A George; Spencer K Sullivan; Adam Giermasz; John E J Rasko; Benjamin J Samelson-Jones; Jonathan Ducore; Adam Cuker; Lisa M Sullivan; Suvankar Majumdar; Jerome Teitel; Catherine E McGuinn; Margaret V Ragni; Alvin Y Luk; Daniel Hui; J Fraser Wright; Yifeng Chen; Yun Liu; Katie Wachtel; Angela Winters; Stefan Tiefenbacher; Valder R Arruda; Johannes C M van der Loo; Olga Zelenaia; Daniel Takefman; Marcus E Carr; Linda B Couto; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

Review 9.  Biological functions of fucose in mammals.

Authors:  Michael Schneider; Esam Al-Shareffi; Robert S Haltiwanger
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

Review 10.  Adeno-associated viral vectors for the treatment of hemophilia.

Authors:  Katherine A High; Xavier M Anguela
Journal:  Hum Mol Genet       Date:  2015-11-27       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.